Fidelity Investments
SABS icon

Fidelity Investments’s SAB Biotherapeutics SABS Stock Holding History

Fidelity Investments’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$452 Buy
+116
New +$432 ﹤0.01% 5320
2024
Q1 		– Sell
-34
Closed -$236 – 5664
2023
Q4 		$236 Hold
34
– – ﹤0.01% 4870
2023
Q3 		$216 Buy
+34
New +$250 ﹤0.01% 4782
2022
Q4 		– Sell
-900
Closed -$6K – 5558
2022
Q3 		$6K Buy
+900
New +$8.93K ﹤0.01% 4265

Other funds holding SABS

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments's SABS Position: Q2 2026 in Review

Fidelity Investments opened a new position in SAB Biotherapeutics (SABS) in Q2 2026: 116 shares worth $452. The stake represents ﹤0.01% of the portfolio and ranks #5320 among its holdings. This is a return to the name: Fidelity Investments previously reported a position in SABS as recently as Q4 2023.

Fidelity Investments first reported a position in SABS in Q3 2022 and has held it in 4 quarters since. The position peaked at $6K in Q3 2022. 87 funds tracked by Wall St. Rank hold SABS as of Q2 2026.

  • Fidelity Investments held 116 shares of SAB Biotherapeutics worth $452 as of Q2 2026.
  • SAB Biotherapeutics was a new Fidelity Investments position in Q2 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #5320 holding.
  • Fidelity Investments first reported a position in SAB Biotherapeutics in Q3 2022 and has held it in 4 quarters since.
  • Fidelity Investments's SAB Biotherapeutics position peaked at $6K in Q3 2022.
  • 87 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.